WeCure Pharma Nordic ApS: Financial statements 2022
CVR: 41349751
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
WeCure Pharma Nordic ApS (CVR 41349751) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 15,442 and a net result of DKK 11,742 compared with DKK 3,875 the year before. That is an increase of 180.6% compared with the year before. Equity in the 2022 report amounted to DKK 48,745. The solvency ratio was 83%.
- Gross Profit
- DKK 15,442
- Profit/Loss
- DKK 11,742
- Equity
- DKK 48,745
- Total Assets
- DKK 58,728
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 15 t. | 12 t. | 49 t. | - |
| 2021 | - | 6 t. | 4 t. | 37 t. | - |
Official annual report
Keep an eye on WeCure Pharma Nordic ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
WeCure Pharma Nordic ApS has published its annual report for 2021. Gross profit came to DKK 5,504, and the net result was DKK 3,875.
About WeCure Pharma Nordic ApS
WeCure Pharma Nordic ApS was a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2020. The company has been dissolved on 14 May 2024. The company was registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. In 2022, the company reported a gross profit of DKK 15,442 and a net result of DKK 11,742 compared with DKK 3,875 the year before. Equity in the 2022 report amounted to DKK 48,745.